Heterocyclic thrombin inhibitors. Part 2: Quinoxalinone derivatives as novel, potent antithrombotic agents

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 14, 2003, Pages 2297-2302

  Ries, Uwe J ^a   Priepke, Henning W M ^a   Hauel, Norbert H ^a   Handschuh, Sandra ^a   Mihm, Gerhard ^a   Stassen, Jean M ^a   Wienen, Wolfgang ^a   Nar, Herbert ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; QUINOXALINE DERIVATIVE; THROMBIN INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; DRUG SYNTHESIS; DRUG TOLERABILITY; ENZYME INHIBITION; IN VITRO STUDY; NONHUMAN; RAT; STRUCTURE ANALYSIS;

EID: 0038004032     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00443-8     Document Type: Article

References (24)

1. (a) Hauptmann J., Stürzebecher J. Thromb. Res. 93:1999;203.
2. (b) Adang A.E.P., Rewinkel J.B.M. Drugs Fut. 25:2000;369.
3. (c) Fevig, J. M., Wexler, R. R., In Annual Reports in Medicinal Chemistry; Greenlee, W., Ed.; Academic Press: San Diego, New York, Boston, London, Sydney, Tokyo, Toronto 1999, Vol. 34, p81.
4. Uwe, J. R.; Priepke, H. W. M.; Hauel, N. H.; Haaksma, E. E. J.; Stassen, J. M.; Wienen, W.; Nar, H. Bioorg. Med. Chem. Lett. See following article. doi:10.1016/S0960-894X(03)00442-6.
5. Weygand F. Liebigs Ann. Chem. 658:1962;128.
6. Chu, V.; Brown, K.; Colussi, D.; Choi, Y. M.; Pauls, H. W.; Perrone, M. H.; Leadley, R. J. Thromb. Haemost Suppl. Abs. 1999 1246.
7. Zhu B.Y., Scarborough R.M. Curr. Opin. Cardiovasc. Pulm. Ren. Invest. Drugs. 1:1999;63.
8. (a) Stubbs M.T., Huber R., Bode W. FEBS Lett. 375:1995;103.
9. (b) Nar H., Bauer M., Schmid A., Stassen J.M., Wienen W., Priepke H.W.M., Kauffmann I.K., Ries U.J., Hauel N.H. Structure. 9:2001;29.
10. 2, R factor 18.9%, R free 21.1%.
11. 13 using MMFF94 charges. During the calculations the factor Xa binding site remained flexible in order to allow possible induced fits. The factor Xa binding site was defined by including residues within a sphere of 7 Å radius around 17 in its trypsin bound position.
12. (a) These side effects have been described elsewhere for amidine and guanidine derivatives: Schumacher W.A., Balasubramanian N., St. Laurent D.R., Seiler S.M. Eur. J. Pharmacol. 259:1994;165.
13. (b) Hauptmann J. Semin. Thromb. Hemost. 18:1992;200.
14. (c) Kaiser B., Hauptmann J. Cardiovasc. Drug Rev. 1:1992;71.
15. (d) Kaiser B., Hauptmann J., Markwardt F. Pharmazie. 42:1987;119.
16. Hauptmann J., Kaiser B., Paintz M., Markwardt F. Pharmazie. 44:1989;282.
17. Stassen, J. M.; Ries, U. J.; Nar H.; Kauffmann-Hefner, I. K.; Priepke, H. W. M.; Hauel, N. H.; Wienen, W. Thromb. Haemost. 2001: Suppl. Abs. P758.
18. MOE Molecular Environment, version 2002.03; Chemical Computing Group Inc.: Montreal, Canada, 2002.
19. (a) Halgren T. Maximally diagonal force constants in dependent angle-bending coordinates. Implications for the design of empirical foerce fields. J. Am. Chem. Soc. 112:1990;4710.
20. (b) Halgern T. MMFF VI, MMFF94s option for energy minimization studies. J. Comp. Chem. 20:1999;720.
21. Bode W., Turk D., Sturzebecher J. Eur. J. Biochem. 193:1990;175.
22. Gewirth D. The HKL Manual. 3rd Edition:1994;Yale University, New Haven CT.
23. Turk D. PhD. Thesis. 1992;TU Muenchen: Muenchen.
24. Brunger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.S., Kuszewski J., Nilges M., Pannu N.S., Read R.J., Rice L.M., Simonson T., Warren G.L. Acta Crystallogr. D Biol. Crystallogr. 54:1998;905.